What are your risk mitigation plans?

Diagnosis rates are the earliest indicator to measure the potential impact to your business.
About Diaceutics
Diaceutics PLC is a leading diagnostic commercialization company for the global pharmaceutical industry. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.
 

What is the COVID-19 Oncology Impact Tracker?

To address growing needs from our customers seeking situational and impact analysis due to the global COVID-19 pandemic, Diaceutics has built a new service offering to provide clarity in these increasingly uncertain times. Based on CDC recommendations, professional organizations such as ASCO have indicated that "any clinic visits that can be postponed without risk to the patient should be postponed. This may potentially include patients who are suspected clinically of disease at low risk of rapid progression.” Our aim is to quantify the impact of these recommendations and redeployed healthcare resources on oncology diagnosis and cancer testing rates.
2020+ forecasting and H1’20 re-forecasting
Salesforce optimization
Resource allocation and timing for deployment 
Development of novel business models and solutions for reaching patients
Scenario planning around required actions to rapidly restart diagnosis when situation resolves 

In this challenging environment, it is critical to remain proactive, which is only possible through real-time data-driven insight into the current landscape.

To learn more, contact us

COVID19 Oncology Impact Tracker

With the Diaceutics COVID-19 Oncology Impact Tracker, you will gain access to real-time monthly data that will give you an early indication of what to expect in the coming months to drive evidence-based decisions around:
In this challenging environment, it is critical to remain proactive, which is only possible through data-driven insights based on the current landscape.
*data represents 58% of all newly diagnosed NSCLC patients in the US market
A monthly dashboard of the volume of patients diagnosed at a disease level.
Relevant biomarkers for each disease area or tumor type will be included in the dashboard
The dashboard will be delivered in the 2nd week of each month and will contain the prior month’s diagnosis data for the relevant disease(s).
This data is representative of the United States market only
All solid and hematologic tumor type data available in line with ICD-10 and CPT coding information

Dashboard Option

Standard: 3 month commitment (includes national and region level analysis)

Standard: 6 month commitment (includes national and region level analysis)

Premium: 3 month commitment (includes state and physician level analysis)

Premium: 6 month commitment (includes state and physician level analysis)

Premium: 12 month commitment (includes state and physician level analysis)

Standard: 12 month commitment (includes national and region level analysis)

*data represents 75% of all newly diagnosed AML patients in the US market

Dashboard Option

Standard: 3 month commitment (includes national and region level analysis)

Standard: 6 month commitment (includes national and region level analysis)

Premium: 3 month commitment (includes state and physician level analysis)

Premium: 6 month commitment (includes state and physician level analysis)

Premium: 12 month commitment (includes state and physician level analysis)

Standard: 12 month commitment (includes national and region level analysis)

To learn more, contact us